What is Prussian Blue Insoluble Formulations?

Table of Contents☰

About Prussian Blue Insoluble Formulations:

It is one of the critical medicines listed by the World Health Organisation for radiological and nuclear emergencies.
It was developed under the Technology Development Fund (TDF).
The drug has been developed based on the technology of the Institute of Nuclear Medicine and Allied Sciences (INMAS), Delhi, a laboratory of the DRDO.
The formulations are used for the decontamination of Cesium and Thallium.
The manufacturing and marketing licenses for the commercial use of the drug have been granted to Scott-Edil Pharmacia Limited, Himachal Pradesh, and Skanttr Lifescience, Gujarat, by DCGI.
The drug will be available under the trade name of Pru-DecorpTM and PruDecorp-MG.

What is the Technology Development Fund (TDF)?

It has been established to promote self-reliance in defense technology as a part of the ‘Make in India’ initiative.
It is a program of the Ministry of Defence executed by DRDO meeting the requirements of Tri-Services, Defence Production, and DRDO.
It supports the indigenous development of components, products, systems, and technologies by MSMEs and start-ups.
Funding:
- The project cost of up to INR 10 Cr will be considered for funding, subject to a maximum of 90% of the total project cost.
- The funding will be through the provision of grants to the industry.

Q1) What is the Central Drugs Standard Control Organisation(CDSCO)?

CDSCO under Directorate General of Health Services,Ministry of Health & Family Welfare,Government of India is the National Regulatory Authority (NRA) of India.CDSCO is responsible for approval of Drugs, Conduct of Clinical Trials, laying down the standards for Drugs, control over the quality of imported Drugs in the country and coordination of the activities of State Drug Control Organizations.

Source: Critical drug used during nuclear emergencies developed on DRDO tech gets approval